Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ferrexpo reels as tax policy disrupts Ukrainian output

(Sharecast News) - Iron ore producer Ferrexpo said on Wednesday that Ukraine's VAT refund suspension had forced it to scale back operations and furlough a significant portion of its workforce. Despite a strong start to the year, Ferrexpo said momentum was curtailed in Q2, forcing it to make deep cost cuts, with the firm reducing stripping rates, cutting non-essential spending, and operating just one pellet line.

Ferrexpo said group revenues fell 33% to $400m, while underlying earnings dropped 42% to $129m, reflecting lower output and weaker pricing. Net cash fell sharply from $109m to just $6m, as liquidity was squeezed by the Ukranian tax authority's decision.

Margins also narrowed, with its EBITDA margin slipping from 41% to 32%. However, Ferrexpo tripled the output of high-grade concentrate to 36% of its overall mix, driven by strong Chinese demand, helping mitigate some of the revenue shortfall.

Ferrexpo also warned that continued VAT disruption could further constrain production and investments. Still, Ferrexpo said it remains committed to supporting Ukraine, noting that it has paid over $340m in taxes and $180m in salaries since the war began.

As of 0835 BST, Ferrexpo shares were up 0.73% at 45.83p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.